Covid19 Clinical Trial
Official title:
Association of Endothelial Damage and Angiogenesis Biomarkers With Morbidity and Mortality in SARS-CoV-2 Infection
Verified date | July 2023 |
Source | University of Chile |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
Severe SARS-CoV-2 disease is characterized by a progressive hypoxemic respiratory failure. Autopsies from these patients show severe endothelial damage with extensive vascular thrombosis, microangiopathy, and occlusion of alveolar capillaries and, finally, evidence of new vessel growth through intussusceptive angiogenesis. This research aims to study endothelial damage and angiogenesis biomarkers and its association with major cardiovascular events.
Status | Completed |
Enrollment | 40 |
Est. completion date | November 30, 2021 |
Est. primary completion date | September 26, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Patients older than 18 years 2. Patient with a diagnosis of COVID-19 confirmed by PCR 3. Patient with radiological image suggestive of COVID-19 with pending confirmation 4. Need for ventilatory support with oxygen therapy by HFNC (High-flow nasal cannula) 5. Need for invasive mechanical ventilation. Exclusion Criteria: 1. Patient with an image suggestive of COVID-19 with negative PCR 2. Anticoagulation users before admission for any reason. |
Country | Name | City | State |
---|---|---|---|
Chile | Hospital Clínico de la Universidad de Chile | Independencia | Santiago |
Lead Sponsor | Collaborator |
---|---|
University of Chile |
Chile,
Maldonado F, Morales D, Diaz-Papapietro C, Valdes C, Fernandez C, Valls N, Lazo M, Espinoza C, Gonzalez R, Gutierrez R, Jara A, Romero C, Cerda O, Caceres M. Relationship Between Endothelial and Angiogenesis Biomarkers Envisage Mortality in a Prospective — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from Baseline Syndecan-1 concentration at 10th day | Elevation of plasma Syndecan-1 | 24 Hours, 10 Days | |
Secondary | Change from Baseline ANG-2 concentration at 10th day | Elevation of plasma ANG-2 | 24 Hours, 10 Days | |
Secondary | Change from Baseline FGF basic concentration at 10th day | Elevation of plasma FGF basic | 24 Hours, 10 Days | |
Secondary | Change from Baseline HGF concentration at 10th day | Elevation of plasma HGF | 24 Hours, 10 Days | |
Secondary | Change from Baseline IL-8 concentration at 10th day | Elevation of plasma IL-8 | 24 Hours, 10 Days | |
Secondary | Change from Baseline PDGF-BB concentration at 10th day | Elevation of plasma PDGF-BB | 24 Hours, 10 Days | |
Secondary | Change from Baseline TIMP-1 concentration at 10th day | Elevation of plasma TIMP-1 | 24 Hours, 10 Days | |
Secondary | Change from Baseline TIMP-2 concentration at 10th day | Elevation of plasma TIMP-2 | 24 Hours, 10 Days | |
Secondary | Change from Baseline TNFa concentration at 10th day | Elevation of plasma TNFa | 24 Hours, 10 Days | |
Secondary | Change from Baseline VEGF concentration at 10th day | Elevation of plasma VEGF | 24 Hours, 10 Days | |
Secondary | Change from Baseline Thrombomodulin concentration at 10th day | Elevation of plasma Thrombomodulin | 24 Hours, 10 Days | |
Secondary | Major cardiovascular events | Acute coronary syndrome, myocardial injury, pulmonary embolism, and death. | 1 month, 3 months, 6 months 12 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |